Elanco

Merck, Synergis & IPS Present on Engineering Document Management for Simplified Compliance & Validation

Retrieved on: 
Monday, November 7, 2022
Software, Architecture, Pharmaceutical, Electronic Design Automation, Technology, Other Manufacturing, Construction & Property, Science, Engineering, Biotechnology, Health, Other Science, Manufacturing, MSD, Associate, Computer, Research, Thermo Fisher Scientific, Compliance, Workflow, EMA, Multimedia, Maintenance, List, Biotechnology, Industry, FDA, Safety, Information management, LLC, Johnson & Johnson, Agilent Technologies, CAD, IPS, Marketing, Construction management, Architecture, Synergy (software), YouTube, Animal, Adept, Frost & Sullivan, Risk, Vaccine, Partnership, Technology, Mining, GxP, Integrity, Risk management, Medical device, Fine chemical, Engineering, Facebook, Merck, Synergy International Systems, Elanco, G2, Bayer, Astellas Pharma

Mr. Lamond and Mr. Niziolek will share their companies roles in supporting MSDs document management implementation and validation.

Key Points: 
  • Mr. Lamond and Mr. Niziolek will share their companies roles in supporting MSDs document management implementation and validation.
  • Adept provides a centralized platform for document access, workflow, and control that aligns engineering, maintenance, operations, and construction teams.
  • Together, Synergis and IPS bring life sciences and biotech companies the best possible solution for engineering document management software coupled with expertise and resources to ensure compliance and validation.
  • Synergis Software , a division of Synergis Technologies, LLC, is a global leader in document management and workflow solutions and is the creator of Synergis Adept software.

TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors

Retrieved on: 
Monday, October 24, 2022
Banking, Professional Services, Finance, TCW Group, Polymer, Therapy, Partner, The Co Founder, Vaccine, Forbes, NYSE, NASDAQ, Board of directors, Refrigeration, ELAN, PETS, Fortune 500, Technology, Company, Acquisition, Board, TCW, CEO, Elanco, Director, Management, Enplug

TCW Special Purpose Acquisition Corp. (NYSE: TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. (TCW), announced that it has appointed Nanxi Liu to the Companys Board of Directors.

Key Points: 
  • TCW Special Purpose Acquisition Corp. (NYSE: TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. (TCW), announced that it has appointed Nanxi Liu to the Companys Board of Directors.
  • Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporations Advisory Board.
  • TCW Special Purpose Acquisition Corp. intends to identify, merge with and take public a durable and predictable business well positioned to deliver superior revenue growth.
  • About TCW Special Purpose Acquisition Corp.
    TCW Special Purpose Acquisition Corp. (the Company), a Delaware corporation, is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with a private company.

Elanco Confirms Date and Conference Call for Third Quarter 2022 Financial Results Announcement

Retrieved on: 
Tuesday, October 11, 2022
Veterinary, Other Consumer, Pets, Other Natural Resources, Other Health, Health, Consumer, Agriculture, Natural Resources, Veterinarian, NYSE, Interpersonal relationship, Farmer, Disease, Health, ELAN, PETS, Animal, Elanco, Pharmaceutical industry, Food

Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2022 financial results on Tuesday, November 8, 2022.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2022 financial results on Tuesday, November 8, 2022.
  • Elanco will also conduct a conference call on that day with the investment community and media to further detail the companys performance.
  • The conference call will begin at 8:00 a.m. eastern time.
  • Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elancos website at https://investor.elanco.com/events-and-presentations/default.aspx .

DENTALIS Animal Health Develops Products to Improve the Oral Health of Companion Animals

Retrieved on: 
Friday, October 7, 2022
Veterinary, Pharmaceutical, Pets, Medical Supplies, Health, Consumer, Dental, Other Health, Regulatory affairs, McDonnell Aircraft Corporation, New product development, Management consulting, Change request, Science, Novartis, Animal, Elanco, Technical, Vaccine, Dentistry, Management

Animal health veterans and human dental experts have combined and formed a start-up company dedicated to the development of superior oral health care products for companion animals, currently developing non-invasive tartar removal products, using an exclusive demonstrated patented technology.

Key Points: 
  • Animal health veterans and human dental experts have combined and formed a start-up company dedicated to the development of superior oral health care products for companion animals, currently developing non-invasive tartar removal products, using an exclusive demonstrated patented technology.
  • The new company, DENTALIS Animal Health, is headquartered in Montreal and is led by:
    President and Product Development Director Kevin McDonnell, serial entrepreneur and co founder of TetraGenx Animal Heath, Provetica AH and Vetio AH.
  • Chief Scientific Officer Hansruedi Siegrist , ex Global Head of Technical Development at Novartis Animal Health and Management Consultant at Elanco AH.
  • We strive to discover new ways to improve and extend our companion animals lives through science based oral health innovation.

Bessemer Investors-backed Pet Flavors Adds VPs David Medina and Cathy Martin

Retrieved on: 
Thursday, October 6, 2022
Marketing, North American Pet Health Insurance Association, Therapy, General manager, Growth, LLC, Vaccine, Hill's Pet Nutrition, Commercial, PETS, Pet, Knowledge, Company, Business development, Hill, USDA, FDA, Solution, Integration, Bottled water, Vegetable oil, Management, Elanco

Pet Flavors is backed by Bessemer Investors LLC ("Bessemer"), a New York-based investment firm that partners with middle-market businesses to support growth and enhance value creation.

Key Points: 
  • Pet Flavors is backed by Bessemer Investors LLC ("Bessemer"), a New York-based investment firm that partners with middle-market businesses to support growth and enhance value creation.
  • "We are excited to welcome David and Cathy to Pet Flavors," said Founder and CEO Mark Pieloch.
  • Ms. Martin joins Pet Flavors from Elanco, where she was Executive Director of U.S. Parasiticides and Pet Health.
  • Both David and Cathy will play key roles in maximizing the value that Pet Flavors and our portfolio of flavoring products bring to the animal health Industry."

Animal Antibiotics and Antimicrobials Global Market to Reach $5.26 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 14, 2022
Pharmaceutical, Agriculture, Health, Natural Resources, Mode, Milk, Human, Diet, Asia-Pacific, Poultry, Meat, Acquisition, Bayer, Growth, Partnership, Industry, Egg, Tetracycline antibiotics, Solution, ADM, Research, PETS, Animal, Livestock, Aquaculture, Animal husbandry, Sulfonamide, Cephalosporin, Aminoglycoside, Elanco, Lincosamides, Macrolide, Penicillin, Injection, Quinolone antibiotic

The "Animal Antibiotics and Antimicrobials Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Animal Antibiotics and Antimicrobials Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • North America was the largest region in the animal antibiotics and antimicrobials market in 2021.
  • The regions covered in the animal antibiotics and antimicrobials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • Rising demand for animal-derived food products is driving the growth of the animal antibiotics and antimicrobials market.

Elanco Announces Changes to its Board of Directors

Retrieved on: 
Thursday, September 8, 2022
Health, Consumer, Agriculture, Natural Resources, Pets, General Health, Veterinary, Partnership, Security (finance), COVID-19, Development, Investor, U.S. Securities and Exchange Commission, Securities Exchange Act of 1934, NYSE, Safety, Securities Act of 1933, Elanco, Insurance, Interpersonal relationship, Disease, Pocumtuck Range, Natural Resources, Board, Risk, Policy, Farmer, Infection, Veterinarian, Information technology, PETS, Animal, Ferguson, Company, Board of directors, Form, Weather, Director, Growth, Health, ELAN, Industry, Forward-looking statement, Management, Risk management, Distribution (marketing), Medical device, Bayer, Food, Sachem

As one of the Companys largest shareholders, Sachem Head will continue to engage with and be a resource for the Board and management team.

Key Points: 
  • As one of the Companys largest shareholders, Sachem Head will continue to engage with and be a resource for the Board and management team.
  • Ferguson said, I am resigning from the Board of Directors to spend additional time on other opportunities in Sachem Heads portfolio and my service on two other public company boards.
  • As the Company executes on its plan, I believe the market will come to appreciate the good work that is being done by management and the Board.
  • The Board and I appreciate Scotts strong partnership and contributions during his tenure as we executed our plans for sustainable growth and enhanced profitability, said R. David Hoover, chairman of Elancos Board of Directors.

United States Veterinary Oncology Market Trends/Analysis Report 2022: A $171.16 Million Market by 2030 - Use of Canines as a Model for Clinical Trials by Researchers Aiding Market Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022
Health, Oncology, Pets, Consumer, Neoplasm, COVID-19, Cancer, Hemangiosarcoma, Osteosarcoma, Therapy, Government, Awareness, Recurrence, Incidence, Dog, Oregon State University, PETS, Lymphoma, Animal, Prevalence, FDA, CAGR, Virbac, Elanco, Risk, Growth, Drug development, Medical imaging, Vaccine, Pharmaceutical industry, Pet, Radiology, Immunotherapy

The market is expected to expand at a CAGR of 8.7% from 2022 to 2030.

Key Points: 
  • The market is expected to expand at a CAGR of 8.7% from 2022 to 2030.
  • Moreover, companies are increasingly adopting strategies, such as M&As, research agreements, collaboration, partnerships, geographic expansion, and product development to enhance their market position.
  • For instance, in November 2020, Virbac publicized the approval of Stelfonta, a novel intratumoral injection treatment for canine mast cell tumors.
  • For instance, in May 2020, PetCure Oncology and Sugar Land Veterinary Specialists publicized a novel radiation oncology service, expanding their network in Houston

Elanco to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Thursday, September 1, 2022
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, CEO, NYSE, Morgan, Interpersonal relationship, Morgan Stanley, Disease, Farmer, Veterinarian, PETS, Animal, Conference, Elanco, Health, ELAN, Food

Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022.
  • Jeff Simmons, president and CEO, will participate in a fireside chat at 2:50 p.m., Eastern time.
  • A live audio webcast will be available in the Events and Presentations section of Elancos investor website .
  • At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our approach to sustainability, Elanco Healthy Purpose all to advance the health of animals, people, planet, and our enterprise.

Elanco Releases 2021 Environmental, Social and Governance Report Highlighting Progress on Healthy Purpose™ Goals

Retrieved on: 
Tuesday, August 16, 2022
Veterinary, Environment, Pets, Professional Services, Health, Consumer, Environmental, Social and Governance (ESG), Agriculture, Natural Resources, People, FDA, Social Security Government Pension Offset, Wind, Multimedia, Disclosure, Adoption, United, Veterinarian, Farmer, Social, NYSE, Interpersonal relationship, Annual general meeting, Dog, Leadership, Guideline, Disease, African, ELAN, Research, Environment, AT, PETS, ESG, Article, Human, Task force, Animal, Sustainability accounting, Biotechnology, Vaccine, Sustainability Accounting Standards Board, Goal, Introduction, Policy, Health, Silent Scope 2, Food and Drug Administration, Articles of incorporation, Ammonia, Antimicrobial stewardship, AT&T, Lithium, Agriculture, Management, Pharmaceutical industry, Livestock, Color, Food, Elanco

Elanco Animal Health Incorporated (NYSE:ELAN) today released its 2021 Environmental, Social and Governance (ESG) Report Changing The World One Animal at a Time highlighting the companys progress on relevant ESG topics and metrics.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE:ELAN) today released its 2021 Environmental, Social and Governance (ESG) Report Changing The World One Animal at a Time highlighting the companys progress on relevant ESG topics and metrics.
  • View the full release here: https://www.businesswire.com/news/home/20220816005184/en/
    Elanco Releases 2021 Environmental, Social and Governance Report Highlighting Progress on Healthy Purpose Goals (Graphic: Business Wire)
    The 2021 ESG Report expands on the companys inaugural 2020 ESG Summary, providing updates on the companys sustainability programs, policies and initiatives as well as metrics and targets in several key areas, including workforce diversity and environmental impact.
  • The 2021 report outlines the companys approach to sustainability, called Elancos Healthy Purpose, and goals which align with the United Nations 2030 Sustainable Development Goals - and annual progress on the four interconnected Healthy Purpose pillars Healthier Animals, Healthier People, Healthier Planet and Healthier Enterprise, focusing on key areas in which the Elanco business can make a difference.
  • The position will report to Marcela Kirberger, executive vice president, general counsel & corporate secretary, who chairs the cross-functional Elanco Healthy Purpose steering committee comprised of senior representation from across our business.